Published in Neurobiol Dis on September 22, 2009
Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci (2010) 1.85
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology (2011) 1.69
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol (2011) 1.22
Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification. J Environ Public Health (2012) 1.08
The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (2014) 1.02
Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener (2010) 0.94
Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis (2010) 0.93
Factors associated with cognitive decline in elderly diabetics. Dement Geriatr Cogn Dis Extra (2011) 0.92
Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging (2014) 0.91
Metabolic reserve as a determinant of cognitive aging. J Alzheimers Dis (2012) 0.89
Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)--and amyloid beta 1-42-induced signal transduction in glial cells. Mol Neurodegener (2012) 0.89
Microglia in Alzheimer brain: a neuropathological perspective. Int J Alzheimers Dis (2012) 0.87
The Complexity of Sporadic Alzheimer's Disease Pathogenesis: The Role of RAGE as Therapeutic Target to Promote Neuroprotection by Inhibiting Neurovascular Dysfunction. Int J Alzheimers Dis (2012) 0.85
Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin (2013) 0.84
Role of RAGE in Alzheimer's Disease. Cell Mol Neurobiol (2015) 0.83
Is There Inflammatory Synergy in Type II Diabetes Mellitus and Alzheimer's Disease? Int J Alzheimers Dis (2012) 0.82
Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics (2012) 0.81
Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. Front Cell Neurosci (2015) 0.80
Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine. Int J Endocrinol (2015) 0.80
Alzheimer's disease promotion by obesity: induced mechanisms-molecular links and perspectives. Curr Gerontol Geriatr Res (2012) 0.79
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
Similar pattern of peripheral neuropathy in mouse models of type 1 diabetes and Alzheimer's disease. Neuroscience (2011) 0.78
Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol Neurobiol (2015) 0.77
Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci (2015) 0.77
Effects of Longitudinal Glucose Exposure on Cognitive and Physical Function: Results from the Action for Health in Diabetes Movement and Memory Study. J Am Geriatr Soc (2016) 0.75
Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model. Sci Rep (2016) 0.75
Amyloid β peptide-mediated neurotoxicity is attenuated by the proliferating microglia more potently than by the quiescent phenotype. J Biomed Sci (2013) 0.75
The diabetic brain and cognition. J Neural Transm (Vienna) (2017) 0.75
Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. Med Sci Monit (2017) 0.75
Retinol (Vitamin A) Increases α-Synuclein, β-Amyloid Peptide, Tau Phosphorylation and RAGE Content in Human SH-SY5Y Neuronal Cell Line. Neurochem Res (2017) 0.75
Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes. Neurobiol Aging (2017) 0.75
[Diabetes mellitus and cognitive decline]. Wien Med Wochenschr (2011) 0.75
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Inclusion bodies: specificity in their aggregation process and amyloid-like structure. Biochim Biophys Acta (2008) 1.24
Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. Neurotoxicology (2004) 1.19
Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J (2005) 1.13
Oxidative stress in Alzheimer disease. Cell Adh Migr (2009) 1.03
Subcellular localization of Arabidopsis 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Plant Physiol (2004) 1.00
Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Brain (2009) 0.96
A diet enriched in polyphenols and polyunsaturated fatty acids, LMN diet, induces neurogenesis in the subventricular zone and hippocampus of adult mouse brain. J Alzheimers Dis (2009) 0.96
Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity. J Biol Chem (2008) 0.93
The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol (2014) 0.93
Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett (2002) 0.93
Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure. FASEB J (2010) 0.91
A single-molecule force spectroscopy nanosensor for the identification of new antibiotics and antimalarials. FASEB J (2010) 0.90
Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia (2008) 0.90
Single-molecule force spectroscopy of cartilage aggrecan self-adhesion. Biophys J (2010) 0.90
Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke (2010) 0.89
PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress. FEBS Lett (2002) 0.89
Proteoglycan mechanics studied by single-molecule force spectroscopy of allotypic cell adhesion glycans. J Biol Chem (2005) 0.88
Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett (2005) 0.88
Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport (2003) 0.87
Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases. Biol Cell (2011) 0.87
A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J Control Release (2011) 0.86
Cyclosporin A suspends transplantation reactions in the marine sponge Microciona prolifera. J Immunol (2007) 0.85
Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity. J Med Chem (2004) 0.85
LMN diet, rich in polyphenols and polyunsaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer's disease. Behav Brain Res (2011) 0.85
The effect of amyloidogenic peptides on bacterial aging correlates with their intrinsic aggregation propensity. J Mol Biol (2011) 0.84
Nanotools for the delivery of antimicrobial peptides. Curr Drug Targets (2012) 0.83
The role of protein sequence and amino acid composition in amyloid formation: scrambling and backward reading of IAPP amyloid fibrils. J Mol Biol (2010) 0.83
VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovasc Dis (2011) 0.83
Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia. Curr Pharm Des (2014) 0.83
Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. Curr Alzheimer Res (2013) 0.82
Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem (2011) 0.81
Effect of diclofenac and glycol intercalation on structural assembly of phospholipid lamellar vesicles. Int J Pharm (2013) 0.81
Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6. Glia (2013) 0.80
In vitro study of magnetite-amyloid β complex formation. Nanomedicine (2011) 0.80
Demonstration of specific binding of heparin to Plasmodium falciparum-infected vs. non-infected red blood cells by single-molecule force spectroscopy. Nanoscale (2013) 0.80
Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J Neural Transm (Vienna) (2012) 0.80
Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur J Med Chem (2012) 0.80
Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J Neurochem (2008) 0.80
The Δ4-desaturation pathway for DHA biosynthesis is operative in the human species: differences between normal controls and children with the Zellweger syndrome. Lipids Health Dis (2010) 0.79
CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. Int J Neurosci (2007) 0.79
Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity. CNS Neurosci Ther (2014) 0.79
Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors. Nanoscale Res Lett (2011) 0.79
Nanotribology results show that DNA forms a mechanically resistant 2D network in metaphase chromatin plates. Biophys J (2010) 0.79
Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus. J Neurosci Res (2012) 0.79
N-cadherin expression is regulated by UTP in schwannoma cells. Purinergic Signal (2012) 0.78
Soluble semicarbazide sensitive amine oxidase (SSAO) catalysis induces apoptosis in vascular smooth muscle cells. Biochim Biophys Acta (2006) 0.78
Topical anti-inflammatory potential of quercetin in lipid-based nanosystems: in vivo and in vitro evaluation. Pharm Res (2013) 0.78
UTP affects the Schwannoma cell line proteome through P2Y receptors leading to cytoskeletal reorganisation. Proteomics (2011) 0.78
Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: a pilot post-mortem study. World J Biol Psychiatry (2010) 0.78
Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Lett (2002) 0.78
Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder. Neurogenetics (2014) 0.78
Sodium bicarbonate enhances membrane-bound and soluble human semicarbazide-sensitive amine oxidase activity in vitro. J Biochem (2007) 0.77
PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem Int (2003) 0.77
Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity. Biomacromolecules (2011) 0.77
Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia. Cerebrovasc Dis (2014) 0.77
The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses. Biochim Biophys Acta (2003) 0.77
SSAO/VAP-1 protein expression during mouse embryonic development. Dev Dyn (2008) 0.77
Mimicking direct protein-protein and solvent-mediated interactions in the CDP-methylerythritol kinase homodimer: a pharmacophore-directed virtual screening approach. J Mol Model (2009) 0.76
Optical tweezers study of topoisomerase inhibition. Small (2009) 0.76
Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim Pol (2010) 0.76
Heparin-functionalized nanocapsules: enabling targeted delivery of antimalarial drugs. Future Med Chem (2013) 0.76
p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1. Biochim Biophys Acta (2008) 0.76
Catecholaminergic and cholinergic systems of mouse brain are modulated by LMN diet, rich in theobromine, polyphenols and polyunsaturated fatty acids. Food Funct (2015) 0.76
A comparison between radiometric and fluorimetric methods for measuring SSAO activity. J Neural Transm (Vienna) (2013) 0.76
Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Med Sci Monit (2004) 0.75
CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes. J Pharm Pharm Sci (2007) 0.75
PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death. Mol Cell Neurosci (2009) 0.75
Synthesis of 4-methyl-thio-phenyl-propylamine and the evaluation of its interaction with different amine oxidases. Bioorg Med Chem (2004) 0.75
Hepatocyte transplants improve liver function and encephalopathy in portacaval shunted rats. CNS Neurosci Ther (2014) 0.75
Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives. Eur J Med Chem (2013) 0.75
Antimicrobial efficacy of 4.2% sodium hypochlorite adjusted to pH 12, 7.5, and 6.5 in infected human root canals. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.75
Effects of ethanol and diclofenac on the organization of hydrogenated phosphatidylcholine bilayer vesicles and their ability as skin carriers. J Mater Sci Mater Med (2015) 0.75
Antimalarial drug delivery to the mosquito: an option worth exploring? Future Microbiol (2014) 0.75
Semicarbazide-sensitive amine oxidases in pig dental pulp. Biochim Biophys Acta (2003) 0.75
A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE. J Neural Transm (Vienna) (2012) 0.75
Toy kit against malaria: magic bullets, LEGO, Trojan horses and Russian dolls. Ther Deliv (2014) 0.75
Monoamine oxidase-B activity is not involved in the neuroinflammatory response elicited by a focal freeze brain injury. J Neurosci Res (2009) 0.75